Introduction
MULTIPLE MYELOMA (MM), INCURABLE DISEASE
Despite recent advancements in therapy, multiple myeloma (MM) is an incurable disease with the majority of patients relapsing after first-line therapy with immunomodulatory drugs, proteasome inhibitors (PIs), or anti-CD38 antibodies [Idecabtagene vicleucel (ide-cel, bb2121) is a B-cell maturation antigen (BCMA)-directed CAR T cell therapy. In the pivotal phase 2 KarMMa trial (NCT03361748), ide-cel demonstrated frequent, deep, and durable responses in triple-class–exposed patients with RRMM [